Form 4 for BIOA BioAge Labs, Inc.
Accepted 2026-04-03 16:07:11 ET · period of report 2026-04-01 · accession 0001210905-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-03 16:07 | 2026-04-01 | BIOA | RUBIN PAUL D | Chief Medical Off | M - OptEx | $5.05 | +8,820 | 8,820 | New | +$44.6K |
| DT | 2026-04-03 16:07 | 2026-04-01 | BIOA | RUBIN PAUL D | Chief Medical Off | S - Sale+OE | $17.81 | -8,820 | 0 | -100% | -$157.1K |
| DMT | 2026-04-03 16:07 | 2026-04-01 | BIOA | RUBIN PAUL D | Chief Medical Off | M - OptEx | $0.00 | -8,820 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | M | A | 5,437 | $4.11 | 5,437 | D | — | — | (F1) The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
| 2 | Common | Common Stock | 2026-04-01 | M | A | 3,383 | $6.57 | 8,820 | D | — | — | (F1) The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
| 3 | Common | Common Stock | 2026-04-01 | S | D | 8,820 | $17.81 | 0 | D | — | — | (F1) The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-04-01 | M | D | 5,437 | $0.00 | 0 | D | $4.11 · — to 2030-06-30 | 5,437 Common Stock | (F1) The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. (F2) This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-04-01 | M | D | 3,383 | $0.00 | 0 | D | $6.57 · — to 2032-05-28 | 3,383 Common Stock | (F1) The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. (F3) The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |